INOVIO Receives FDA Breakthrough Therapy Designation For INO-3107 For Recurrent Respiratory Papillomatosis
Portfolio Pulse from Benzinga Newsdesk
INOVIO Pharmaceuticals has received FDA Breakthrough Therapy Designation for its drug INO-3107, intended for the treatment of Recurrent Respiratory Papillomatosis.
September 07, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INOVIO Pharmaceuticals' stock may see positive movement due to the FDA Breakthrough Therapy Designation for INO-3107.
The FDA Breakthrough Therapy Designation is given to expedite the development and review of drugs intended to treat serious conditions. This designation for INO-3107 could lead to faster approval and market entry, potentially boosting INOVIO's revenues and positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100